Timelines and Review Expectations for Emergency Use Filings – regulations in the pharmaceutical industry Timelines and Review Expectations for Emergency Use Filings Emergency Use Filings (EUF) are crucial regulatory pathways that allow healthcare providers to access unapproved medical products during public health emergencies. Understanding the timelines and review expectations associated with these filings is essential for stakeholders in the pharmaceutical industry. This tutorial will guide you through practical steps on how to navigate the complexities of EUF, particularly under the frameworks set forth by regulatory authorities such as the FDA, EMA, and other global agencies. Step 1: Understanding the Regulatory…

Comparison of Compassionate Use Regulations in US, EU, and India – senior director pharmacovigilance Comparison of Compassionate Use Regulations in US, EU, and India Compassionate use, also known as expanded access, is a critical provision in regulatory frameworks allowing patients with serious or life-threatening conditions to gain access to investigational therapies. This tutorial provides a comprehensive comparison of compassionate use regulations in the US, EU, and India, focusing on the practical actions and documentation requirements expected by regulatory authorities. This guide is particularly beneficial for professionals involved in senior director pharmacovigilance roles. Step 1: Understanding the Regulatory Framework for Compassionate…

Regulatory Risk Management in Expanded Access Programs – raps regulatory affairs professional society Regulatory Risk Management in Expanded Access Programs In recent years, expanded access programs (EAP) have become significant avenues for patients who have no other therapeutic options to access investigational drugs or devices. Regulatory authorities such as the FDA, EMA, and others recognize the importance of these programs and the need for effective regulatory risk management within them. This tutorial aims to provide professionals within the pharmaceutical industry, specifically those affiliated with organizations like the raps regulatory affairs professional society, with a step-by-step guide to the regulatory processes…

Expanded Access Programs for Rare or Life-Threatening Conditions – FDA Regulations Pharmaceutical Industry Expanded Access Programs for Rare or Life-Threatening Conditions under FDA Regulations Expanded access programs (EAP) provide patients with access to investigational treatments for serious or life-threatening conditions when no satisfactory alternatives are available. It is also known as compassionate use. This article serves as a comprehensive step-by-step tutorial aimed at regulatory, clinical, and quality assurance professionals seeking to navigate the complexities of these programs under FDA regulations. The content is structured to provide clear guidance in alignment with ICH-GCP, FDA, EMA, and related regulations. Step 1: Understanding…

Case Study: Compassionate Use of Experimental Oncology Drug – medical affairs pharmacy Case Study: Compassionate Use of Experimental Oncology Drug – medical affairs pharmacy This tutorial provides a detailed step-by-step guide on navigating the regulatory landscape associated with the compassionate use of experimental oncology drugs, specifically through expanded access programs. This guide is targeted at professionals in the regulatory affairs, clinical, quality assurance, and medical affairs pharmacy sectors, focusing on the practical actions, documentation expectations, and regulatory nuances that must be adhered to within the framework of FDA, EMA, MHRA, and related guidelines. Understanding the Framework: Regulatory Pathways for Compassionate…